Novelos Therapeutics And Musc Peer Reviewed Article Published In Expert Opinion On Investigational Drugs

"NOV-002, a Mimetic of Glutathione Disulfide"

(PresseBox) ( Newton, Massachusetts, )
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos' peer reviewed article, based on the collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Medical University of South Carolina(MUSC), has been published in Expert Opinion on Investigational Drugs [Volume 17, Issue 7, pages 1075-1083, 2008]. This article describes clinical results as well as findings in cellular and animal model systems that demonstrate the ability of NOV-002 to influence redox balance in and on cells, resulting in a constellation of effects on redox-sensitive cell processes and functions.
NOV-002 is the subject of an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track, having also demonstrated positive results in Phase 2 trials for other oncology indications.

"We are very pleased to have another peer reviewed publication, continuing to establish cellular redox modulation as the fundamental mechanism of action of NOV-002," said Christopher Pazoles, Ph.D., Vice President of Research & Development of Novelos. "This article strengthens the connection between NOV-002 and an emerging literature that has shown redox status to be a key regulator of signal pathway activation, cell proliferation, cytoskeleton changes and other cell functions that may relate to NOV-002's unique therapeutic profile, which is also described in the article."

The article is available at www.novelos.com 'Our Products', 'NOV-002' section.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.